CU20130033A7 - Imidazopiridazinas sustituidas - Google Patents
Imidazopiridazinas sustituidasInfo
- Publication number
- CU20130033A7 CU20130033A7 CU2013000033A CU20130033A CU20130033A7 CU 20130033 A7 CU20130033 A7 CU 20130033A7 CU 2013000033 A CU2013000033 A CU 2013000033A CU 20130033 A CU20130033 A CU 20130033A CU 20130033 A7 CU20130033 A7 CU 20130033A7
- Authority
- CU
- Cuba
- Prior art keywords
- compounds
- imidazopiridazinas
- replaced
- kinase
- ttk
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102100036109 Dual specificity protein kinase TTK Human genes 0.000 abstract 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 150000005233 imidazopyridazines Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Paper (AREA)
Abstract
La presente invención se relaciona con compuestos de imidazopiridazina sustituida de la fórmula general I, que son inhibidores de la quinasa Mps-1(del uso monopolar 1) (también conocidos como quinasa de tirosina y treonina,TTK) donde R^3, R^5 y A son como se definen en la descrpción y en las reivindicaciones. Métodos para preparar dichos compuestos.Composiciones y combinaciones farmacéuticas que comprenden dichos compuestos. Uso de dichos compuestos para preparar una composición farmacéuticamente para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o angiogenésis, como un único agente o en combinación con otros ingredientes activos.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10176134 | 2010-09-10 | ||
| EP11075022 | 2011-02-04 | ||
| EP11170775 | 2011-06-21 | ||
| EP11170771 | 2011-06-21 | ||
| PCT/EP2011/065368 WO2012032031A1 (en) | 2010-09-10 | 2011-09-06 | Substituted imidazopyridazines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20130033A7 true CU20130033A7 (es) | 2013-08-29 |
| CU24187B1 CU24187B1 (es) | 2016-07-29 |
Family
ID=44545741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2013000033A CU24187B1 (es) | 2010-09-10 | 2011-09-06 | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US9255100B2 (es) |
| EP (1) | EP2614063B1 (es) |
| JP (1) | JP5824050B2 (es) |
| KR (1) | KR20140032337A (es) |
| CN (1) | CN103370318B (es) |
| AP (1) | AP3607A (es) |
| AR (1) | AR082946A1 (es) |
| AU (1) | AU2011298844B2 (es) |
| BR (1) | BR112013005679A2 (es) |
| CA (1) | CA2810755A1 (es) |
| CO (1) | CO6720961A2 (es) |
| CR (1) | CR20130102A (es) |
| CU (1) | CU24187B1 (es) |
| CY (1) | CY1117352T1 (es) |
| DK (1) | DK2614063T3 (es) |
| DO (1) | DOP2013000054A (es) |
| EA (1) | EA023420B1 (es) |
| EC (1) | ECSP13012752A (es) |
| ES (1) | ES2568220T3 (es) |
| HR (1) | HRP20160360T1 (es) |
| HU (1) | HUE028771T2 (es) |
| IL (1) | IL225058A (es) |
| MA (1) | MA34516B1 (es) |
| ME (1) | ME02389B (es) |
| MX (1) | MX2013002713A (es) |
| MY (1) | MY185139A (es) |
| NZ (1) | NZ607904A (es) |
| PE (1) | PE20131164A1 (es) |
| PH (1) | PH12013500454A1 (es) |
| PL (1) | PL2614063T3 (es) |
| RS (1) | RS54661B1 (es) |
| SA (1) | SA111320735B1 (es) |
| SG (1) | SG188417A1 (es) |
| SI (1) | SI2614063T1 (es) |
| TW (1) | TWI541243B (es) |
| UY (1) | UY33598A (es) |
| WO (1) | WO2012032031A1 (es) |
| ZA (1) | ZA201301756B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| EP2734205B1 (en) | 2011-07-21 | 2018-03-21 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| JP6166289B2 (ja) * | 2012-03-14 | 2017-07-19 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリダジン |
| LT3495367T (lt) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| JP6377068B2 (ja) | 2012-11-16 | 2018-08-22 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| TW201437211A (zh) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | 經取代咪唑并嗒□ |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| PE20160156A1 (es) | 2013-06-11 | 2016-04-20 | Bayer Pharma AG | Derivados de prodroga de triazolpiridinas sustituidas |
| CA2914995A1 (en) * | 2013-06-13 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer |
| CN103360399B (zh) * | 2013-08-02 | 2016-03-02 | 北京大学 | 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途 |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| CA2940237C (en) * | 2014-02-21 | 2023-03-07 | Frost Biologic, Inc. | Antimitotic amides for the treatment of cancer and proliferative disorders |
| WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| TW201613927A (en) * | 2014-09-01 | 2016-04-16 | Bayer Pharma AG | Method for preparation of substituted imidazopyridazines |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| SG11201706287PA (en) | 2015-02-20 | 2017-09-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| EP3283642B1 (en) | 2015-04-17 | 2023-10-11 | Netherlands Translational Research Center Holding B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
| WO2016187028A1 (en) * | 2015-05-15 | 2016-11-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds, synthesis thereof, and intermediates thereto |
| RU2721569C2 (ru) * | 2015-12-04 | 2020-05-20 | ЭкссонМобил Рисерч энд Энджиниринг Компани | EMM-28 - новый синтетический кристаллический материал, его получение и применение |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| IL264173B2 (en) | 2016-07-18 | 2025-05-01 | Univ Health Network | Solid forms of ttk inhibitor |
| EP3609547B1 (en) * | 2017-04-11 | 2021-10-06 | Straumann Holding AG | Dental implant |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| ES3061844T3 (en) | 2018-05-04 | 2026-04-07 | Incyte Corp | Salts of an fgfr inhibitor |
| MX2020011718A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas. |
| HUE068695T2 (hu) | 2018-05-08 | 2025-01-28 | Nippon Shinyaku Co Ltd | Azabenzimidazol vegyületek és gyógyszerek |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| AU2020221247B2 (en) | 2019-02-12 | 2024-12-12 | Sumitomo Pharma America, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CN111978325B (zh) * | 2019-05-22 | 2023-11-17 | 中国药科大学 | 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12528813B2 (en) | 2019-11-13 | 2026-01-20 | Nippon Shinyaku Co., Ltd. | Substituted imidazo[4,5-b]pyridines as M3 receptor PAMs |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| MX2024007450A (es) * | 2021-12-15 | 2024-07-04 | Sillajen Inc | Combinaciones farmaceuticas para utilizarse en el tratamiento de enfermedades neoplasicas. |
| AU2024209823A1 (en) * | 2023-01-19 | 2025-07-31 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199900389T2 (xx) | 1996-08-28 | 2000-06-21 | Pfizer Inc. | �kame edilmi� 6,5-hetero-bisiklik t�revleri. |
| AU2001252609A1 (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd. | Imidazopyridine derivatives |
| TWI335328B (en) | 2003-07-14 | 2011-01-01 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto |
| EP1713784A1 (en) | 2004-02-12 | 2006-10-25 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| CA2628455A1 (en) * | 2005-11-10 | 2007-05-24 | Merck Sharp & Dohme Corp. | Imidazopyrazines as protein kinase inhibitors |
| TW200840584A (en) * | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
| WO2008130951A1 (en) * | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
| WO2009060197A1 (en) | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
| EP2240488B1 (en) | 2008-02-06 | 2016-11-02 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| ES2547328T3 (es) | 2009-04-29 | 2015-10-05 | Bayer Intellectual Property Gmbh | Imidazoquinoxalinas sustituidas |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| JP5728683B2 (ja) | 2009-09-04 | 2015-06-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| ES2551407T3 (es) | 2010-03-18 | 2015-11-18 | Bayer Intellectual Property Gmbh | Imidazopirazinas |
| WO2011151259A1 (en) | 2010-06-01 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyrazines |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| WO2012080228A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| EP2651944B1 (en) | 2010-12-17 | 2015-09-23 | Bayer Intellectual Property GmbH | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CA2821819A1 (en) | 2010-12-17 | 2012-06-21 | Marcus Koppitz | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| ES2544609T3 (es) | 2010-12-17 | 2015-09-02 | Bayer Intellectual Property Gmbh | Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos |
| CA2821829A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CN103429591A (zh) | 2010-12-17 | 2013-12-04 | 拜耳知识产权有限责任公司 | 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪 |
-
2011
- 2011-08-25 TW TW100130542A patent/TWI541243B/zh not_active IP Right Cessation
- 2011-09-06 RS RS20160221A patent/RS54661B1/sr unknown
- 2011-09-06 SI SI201130761A patent/SI2614063T1/sl unknown
- 2011-09-06 EP EP11751910.8A patent/EP2614063B1/en active Active
- 2011-09-06 JP JP2013527575A patent/JP5824050B2/ja not_active Expired - Fee Related
- 2011-09-06 CU CUP2013000033A patent/CU24187B1/es active IP Right Grant
- 2011-09-06 MY MYPI2013700375A patent/MY185139A/en unknown
- 2011-09-06 AP AP2013006790A patent/AP3607A/xx active
- 2011-09-06 MX MX2013002713A patent/MX2013002713A/es active IP Right Grant
- 2011-09-06 EA EA201390339A patent/EA023420B1/ru not_active IP Right Cessation
- 2011-09-06 BR BR112013005679A patent/BR112013005679A2/pt not_active IP Right Cessation
- 2011-09-06 PL PL11751910T patent/PL2614063T3/pl unknown
- 2011-09-06 MA MA35720A patent/MA34516B1/fr unknown
- 2011-09-06 WO PCT/EP2011/065368 patent/WO2012032031A1/en not_active Ceased
- 2011-09-06 HU HUE11751910A patent/HUE028771T2/en unknown
- 2011-09-06 CA CA2810755A patent/CA2810755A1/en not_active Abandoned
- 2011-09-06 NZ NZ607904A patent/NZ607904A/en not_active IP Right Cessation
- 2011-09-06 DK DK11751910.8T patent/DK2614063T3/en active
- 2011-09-06 PE PE2013000392A patent/PE20131164A1/es not_active Application Discontinuation
- 2011-09-06 US US13/822,175 patent/US9255100B2/en not_active Expired - Fee Related
- 2011-09-06 HR HRP20160360TT patent/HRP20160360T1/hr unknown
- 2011-09-06 CN CN201180054217.5A patent/CN103370318B/zh not_active Expired - Fee Related
- 2011-09-06 PH PH1/2013/500454A patent/PH12013500454A1/en unknown
- 2011-09-06 ES ES11751910.8T patent/ES2568220T3/es active Active
- 2011-09-06 SG SG2013016480A patent/SG188417A1/en unknown
- 2011-09-06 AU AU2011298844A patent/AU2011298844B2/en not_active Ceased
- 2011-09-06 ME MEP-2016-63A patent/ME02389B/me unknown
- 2011-09-06 KR KR1020137009011A patent/KR20140032337A/ko not_active Ceased
- 2011-09-07 SA SA111320735A patent/SA111320735B1/ar unknown
- 2011-09-08 UY UY0001033598A patent/UY33598A/es unknown
- 2011-09-09 AR ARP110103294A patent/AR082946A1/es unknown
-
2013
- 2013-03-05 IL IL225058A patent/IL225058A/en active IP Right Grant
- 2013-03-07 ZA ZA2013/01756A patent/ZA201301756B/en unknown
- 2013-03-08 DO DO2013000054A patent/DOP2013000054A/es unknown
- 2013-03-08 CR CR20130102A patent/CR20130102A/es unknown
- 2013-03-08 CO CO13047157A patent/CO6720961A2/es active IP Right Grant
- 2013-03-08 EC ECSP13012752 patent/ECSP13012752A/es unknown
-
2016
- 2016-04-12 CY CY20161100294T patent/CY1117352T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2013000054A (es) | Imidazopiridazinas sustituidas | |
| DOP2019000110A (es) | 1,2,4triazolonas 2,4,5trisustituidas | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| JO3447B1 (ar) | 2-(مورفولين-4-يل)-7،1-نفثيريدينات | |
| MX2014002697A (es) | Imidazopiridazinas sustituidas con amino. | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| CY1119667T1 (el) | Υποκατεστημενες ιμιδαζοπυριδαζινες | |
| UY31780A (es) | Fenoxibenzamidas sustituidas | |
| PH12017501133A1 (en) | Pyrazolopyridinamines | |
| UY37577A (es) | Dihidroimidazopiridindionas sustituidas | |
| PH12016500054A1 (en) | Substituted pyrazolo-pyridinamines | |
| UY35848A (es) | Tienopirimidinas | |
| WO2015150449A3 (en) | Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2 | |
| UY37444A (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso | |
| UY36983A (es) | Pirazolopiridinaminas sustituidas | |
| TN2013000099A1 (en) | Substituted imidazopyridazines | |
| AR094934A1 (es) | Imidazopiridazinas sustituidas | |
| TN2014000091A1 (en) | Amino-substituted imidazopyridazines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |